Hologic, Inc. (NASDAQ:HOLX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Hologic, Inc. (NASDAQ:HOLX – Get Rating) has earned a consensus recommendation of “Hold” from the sixteen research firms that are covering the company, MarketBeat reports. Seven analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $86.00.

A number of equities analysts recently issued reports on the company. Raymond James boosted their price objective on Hologic from $95.00 to $100.00 in a report on Tuesday, May 2nd. Morgan Stanley boosted their price objective on Hologic from $74.00 to $81.00 and gave the company an “equal weight” rating in a report on Friday, February 3rd. StockNews.com assumed coverage on Hologic in a report on Thursday, May 18th. They set a “buy” rating for the company. SVB Leerink boosted their price objective on Hologic from $90.00 to $93.00 and gave the company an “outperform” rating in a report on Thursday, February 2nd. Finally, Mizuho boosted their price objective on Hologic from $92.00 to $95.00 in a report on Tuesday, May 2nd.

Insider Transactions at Hologic

In other news, insider Essex D. Mitchell sold 2,390 shares of the business’s stock in a transaction on Friday, May 5th. The stock was sold at an average price of $83.73, for a total value of $200,114.70. Following the completion of the transaction, the insider now directly owns 7,212 shares of the company’s stock, valued at approximately $603,860.76. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 1.66% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its position in Hologic by 5.1% during the 1st quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 33,448 shares of the medical equipment provider’s stock valued at $2,569,000 after buying an additional 1,631 shares in the last quarter. LSV Asset Management increased its position in Hologic by 307.5% during the 1st quarter. LSV Asset Management now owns 37,900 shares of the medical equipment provider’s stock valued at $2,911,000 after buying an additional 28,600 shares in the last quarter. Raymond James Trust N.A. increased its position in Hologic by 7.4% during the 1st quarter. Raymond James Trust N.A. now owns 6,875 shares of the medical equipment provider’s stock valued at $528,000 after buying an additional 476 shares in the last quarter. Dimensional Fund Advisors LP increased its position in Hologic by 4.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,305,399 shares of the medical equipment provider’s stock valued at $177,098,000 after buying an additional 106,315 shares in the last quarter. Finally, Aviva PLC increased its position in Hologic by 0.7% during the 1st quarter. Aviva PLC now owns 75,543 shares of the medical equipment provider’s stock valued at $5,803,000 after buying an additional 513 shares in the last quarter. 95.17% of the stock is owned by institutional investors.

Hologic Price Performance

Shares of Hologic stock opened at $79.03 on Friday. The stock has a market cap of $19.45 billion, a price-to-earnings ratio of 26.43 and a beta of 1.00. The company has a debt-to-equity ratio of 0.53, a quick ratio of 3.69 and a current ratio of 4.41. The stock has a 50 day moving average price of $82.13 and a 200-day moving average price of $79.57. Hologic has a one year low of $59.78 and a one year high of $87.88.

Hologic (NASDAQ:HOLX – Get Rating) last announced its earnings results on Monday, May 1st. The medical equipment provider reported $1.06 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.18. The firm had revenue of $1.03 billion during the quarter, compared to analysts’ expectations of $957.53 million. Hologic had a return on equity of 19.39% and a net margin of 18.56%. The company’s quarterly revenue was down 28.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.07 EPS. Equities analysts expect that Hologic will post 3.89 EPS for the current year.

Hologic Company Profile

(Get Rating)

Hologic, Inc engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment includes a portfolio of solutions for breast cancer care for radiology, pathology, and surgery.